Plain-English translation of NCT04777916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large study that will follow up to 5,000 adults with acute myeloid leukemia (AML)—a serious blood cancer—to see how they are treated and how they do over time. Rather than testing a new drug, researchers will track patients receiving standard treatments that doctors already use, including chemotherapy options like the 3+7 regimen, gemtuzumab ozogamicin (Mylotarg), Vyxeos, and other approved medications. The goal is to understand how patients are actually treated in real life and what their outcomes are.
Over the past 15 years, doctors have many more treatment choices for acute myeloid leukemia, including new drugs and new transplant procedures. However, not all patients enter formal clinical trials, so researchers don't have good information about how standard treatments work for the average patient outside of those trials. This study will fill that gap by documenting real-world treatment patterns and outcomes.
You likely qualify if…
You likely don't qualify if…
You would not receive any new or experimental medication—instead, researchers would follow your regular cancer care with your doctor and collect information about your treatments and health outcomes over time. Your participation would involve allowing the research team to access and review your medical records, including details about which treatments you received, how you responded, and any side effects. The study does not require additional visits or procedures beyond your normal cancer care appointments.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France